Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2019

28.02.2019 | Original Article

Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care

verfasst von: Shirley Cohen-Mekelburg, Yecheskel Schneider, Stephanie Gold, Gaurav Ghosh, Russell Rosenblatt, Kaveh Hajifathalian, Ellen Scherl, Felice Schnoll-Sussman, Philip Katz, Adam Steinlauf

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Current guidelines recommend starting colorectal cancer (CRC) surveillance 8–10 years after inflammatory bowel disease (IBD) onset. Recent studies report that the incidence of CRC within 8–10 years of IBD onset (i.e., early CRC) ranges from 12 to 42%.

Aims

To describe the current prevalence of early CRC in a tertiary care center IBD cohort with CRC and to identify associated risk factors.

Methods

We performed a single-center observational study of IBD patients diagnosed with CRC from 2005 to 2015. We compared characteristics of patients with early CRC (diagnosis of CRC within 8 years of initial IBD onset) to those with CRC diagnosed later in their IBD course.

Results

Ninety-three patients met inclusion criteria. Eleven (11.8%) patients developed CRC within 8 years of initial IBD onset. On multivariable logistic regression, age greater than 28 at IBD onset (adjusted OR 12.0; 95% CI 2.30, 62.75) and tobacco use (adjusted OR 8.52; 95% CI 1.38, 52.82) were significant predictors of early CRC. A validation cohort confirmed calibration and discrimination of the model.

Conclusions

One out of every eight IBD patients with CRC developed their malignancy prior to the currently recommended timeframe for the initiation of surveillance colonoscopy. IBD onset at 28 years or older and tobacco use were identified as predictors of early CRC. Early CRC should be considered in discussions of cancer surveillance in this population. Prospective cohort studies are necessary to further analyze the impact of early CRC in IBD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–2729.CrossRefPubMed Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–2729.CrossRefPubMed
3.
Zurück zum Zitat Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–G17.CrossRefPubMed Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–G17.CrossRefPubMed
4.
Zurück zum Zitat Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case–control study. Cancer. 1998;82:822–826.CrossRefPubMed Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case–control study. Cancer. 1998;82:822–826.CrossRefPubMed
5.
Zurück zum Zitat Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342.e1–1348.e1. Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342.e1–1348.e1.
6.
Zurück zum Zitat Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–1362.CrossRefPubMed Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–1362.CrossRefPubMed
7.
Zurück zum Zitat Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case–control study. Gastroenterology. 1998;115:1079–1083.CrossRefPubMed Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case–control study. Gastroenterology. 1998;115:1079–1083.CrossRefPubMed
8.
Zurück zum Zitat Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case–control study. Aliment Pharmacol Ther. 2000;14:145–153.CrossRefPubMed Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case–control study. Aliment Pharmacol Ther. 2000;14:145–153.CrossRefPubMed
9.
Zurück zum Zitat Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46–55.CrossRefPubMed Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46–55.CrossRefPubMed
10.
Zurück zum Zitat Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459.CrossRefPubMed Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459.CrossRefPubMed
11.
Zurück zum Zitat Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246–1251.CrossRefPubMed Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246–1251.CrossRefPubMed
12.
Zurück zum Zitat Jess T, Loftus EV, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case–control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007;102:829–836.CrossRefPubMed Jess T, Loftus EV, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case–control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007;102:829–836.CrossRefPubMed
13.
Zurück zum Zitat Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233.CrossRefPubMed Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233.CrossRefPubMed
14.
Zurück zum Zitat Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case–control study. Gastroenterology. 2006;130:1941–1949.CrossRefPubMed Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case–control study. Gastroenterology. 2006;130:1941–1949.CrossRefPubMed
15.
Zurück zum Zitat Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.CrossRefPubMedPubMedCentral Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48:1405–1413.CrossRefPubMed Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013;48:1405–1413.CrossRefPubMed
17.
Zurück zum Zitat Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697–1703.CrossRefPubMed Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697–1703.CrossRefPubMed
18.
Zurück zum Zitat Itzkowitz SH, Present DH, Group CsaCFoACCiIS. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321.CrossRefPubMed Itzkowitz SH, Present DH, Group CsaCFoACCiIS. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321.CrossRefPubMed
19.
Zurück zum Zitat Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–3947.CrossRefPubMedPubMedCentral Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–3947.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–1038.CrossRefPubMed Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–1038.CrossRefPubMed
21.
Zurück zum Zitat Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.CrossRefPubMed Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.CrossRefPubMed
22.
Zurück zum Zitat Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed
23.
Zurück zum Zitat Eaden JA, Mayberry JF, Gastroenterology BSf, Ireland AoCfGBa. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:V10-2.CrossRefPubMed Eaden JA, Mayberry JF, Gastroenterology BSf, Ireland AoCfGBa. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:V10-2.CrossRefPubMed
24.
Zurück zum Zitat Gaidos JK, Bickston SJ. How to optimize colon cancer surveillance in inflammatory bowel disease patients. Inflamm Bowel Dis. 2016;22:1219–1230.CrossRefPubMed Gaidos JK, Bickston SJ. How to optimize colon cancer surveillance in inflammatory bowel disease patients. Inflamm Bowel Dis. 2016;22:1219–1230.CrossRefPubMed
25.
Zurück zum Zitat Sebastian S, Hernández V, Myrelid P, et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis. 2014;8:5–18.CrossRefPubMed Sebastian S, Hernández V, Myrelid P, et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis. 2014;8:5–18.CrossRefPubMed
26.
Zurück zum Zitat Gordillo J, Cabré E, Garcia-Planella E, et al. Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry. J Crohns Colitis. 2015;9:1063–1070.CrossRefPubMed Gordillo J, Cabré E, Garcia-Planella E, et al. Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry. J Crohns Colitis. 2015;9:1063–1070.CrossRefPubMed
27.
Zurück zum Zitat Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–138.CrossRefPubMedPubMedCentral Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–138.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn’s and ulcerative colitis based on three decades of experience. Ann Surg. 2010;252:330–335.CrossRefPubMed Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn’s and ulcerative colitis based on three decades of experience. Ann Surg. 2010;252:330–335.CrossRefPubMed
29.
Zurück zum Zitat Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–1592.CrossRefPubMedPubMedCentral Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–1592.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193.CrossRefPubMed Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193.CrossRefPubMed
31.
Zurück zum Zitat Qiu X, Ma J, Wang K, Zhang H. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017;8:1031–1045.PubMed Qiu X, Ma J, Wang K, Zhang H. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017;8:1031–1045.PubMed
32.
Zurück zum Zitat Salk JJ, Bansal A, Lai LA, et al. Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflamm Bowel Dis. 2013;19:2593–2602.CrossRefPubMed Salk JJ, Bansal A, Lai LA, et al. Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflamm Bowel Dis. 2013;19:2593–2602.CrossRefPubMed
33.
Zurück zum Zitat Jonsson B, Ahsgren L, Andersson LO, Stenling R, Rutegård J. Colorectal cancer surveillance in patients with ulcerative colitis. Br J Surg. 1994;81:689–691.CrossRefPubMed Jonsson B, Ahsgren L, Andersson LO, Stenling R, Rutegård J. Colorectal cancer surveillance in patients with ulcerative colitis. Br J Surg. 1994;81:689–691.CrossRefPubMed
34.
Zurück zum Zitat Giardiello FM, Gurbuz AK, Bayless TM, Goodman SN, Yardley JH. Colorectal cancer in ulcerative colitis: survival in patients with and without colorectal cancer symptoms. Inflamm Bowel Dis. 1996;2:6–10.CrossRefPubMed Giardiello FM, Gurbuz AK, Bayless TM, Goodman SN, Yardley JH. Colorectal cancer in ulcerative colitis: survival in patients with and without colorectal cancer symptoms. Inflamm Bowel Dis. 1996;2:6–10.CrossRefPubMed
35.
Zurück zum Zitat Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006;2:CD000279. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006;2:CD000279.
36.
Zurück zum Zitat Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671–1675.CrossRefPubMedPubMedCentral Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671–1675.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166.e8–175.e8. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166.e8–175.e8.
38.
Zurück zum Zitat Siegel CA, Lofland JH, Naim A, et al. Novel statistical approach to determine inflammatory bowel disease: patients’ perspectives on shared decision making. Patient. 2016;9:79–89.CrossRefPubMed Siegel CA, Lofland JH, Naim A, et al. Novel statistical approach to determine inflammatory bowel disease: patients’ perspectives on shared decision making. Patient. 2016;9:79–89.CrossRefPubMed
Metadaten
Titel
Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care
verfasst von
Shirley Cohen-Mekelburg
Yecheskel Schneider
Stephanie Gold
Gaurav Ghosh
Russell Rosenblatt
Kaveh Hajifathalian
Ellen Scherl
Felice Schnoll-Sussman
Philip Katz
Adam Steinlauf
Publikationsdatum
28.02.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05554-1

Weitere Artikel der Ausgabe 8/2019

Digestive Diseases and Sciences 8/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.